80_FR_8361 80 FR 8330 - National Institute of Environmental Health Sciences; Notice of Closed Meeting

80 FR 8330 - National Institute of Environmental Health Sciences; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 31 (February 17, 2015)

Page Range8330-8331
FR Document2015-03094

Federal Register, Volume 80 Issue 31 (Tuesday, February 17, 2015)
[Federal Register Volume 80, Number 31 (Tuesday, February 17, 2015)]
[Notices]
[Pages 8330-8331]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-03094]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Environmental Health Sciences; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Environmental Health 
Sciences Special Emphasis Panel; Worker Health and Safety Training 
Review.
    Date: March 9-10, 2015.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Sheraton Chapel Hill Hotel, One Europa Drive, Chapel 
Hill, NC 27517.

[[Page 8331]]

    Contact Person: Sally Eckert-Tilotta, Ph.D., Scientific Review 
Officer, National Institute of Environmental Health Sciences, Office 
of Program Operations, Scientific Review Branch, P.O. Box 12233, 
Research Triangle Park, NC 27709, (919) 541-1446, 
eckertt1@niehs.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.115, 
Biometry and Risk Estimation--Health Risks from Environmental 
Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety 
Training; 93.143, NIEHS Superfund Hazardous Substances--Basic 
Research and Education; 93.894, Resources and Manpower Development 
in the Environmental Health Sciences; 93.113, Biological Response to 
Environmental Health Hazards; 93.114, Applied Toxicological Research 
and Testing, National Institutes of Health, HHS)

    Dated: February 10, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-03094 Filed 2-13-15; 8:45 am]
BILLING CODE 4140-01-P



                                              8330                        Federal Register / Vol. 80, No. 31 / Tuesday, February 17, 2015 / Notices

                                              Therefore, selection of potential                       21 May 2010 [HHS Ref. E–191–2009/0–                   small business initiative launched on 1
                                              facilities will be based on the                         PCT–02]. The patent rights in this                    October 2011, and will comply with the
                                              coordination of CBER’s priorities for                   invention have been assigned to the                   terms and conditions of 35 U.S.C. 209
                                              staff training as well as the limited                   Government of the United States of                    and 37 CFR part 404. The prospective
                                              available resources for this program. In                America.                                              exclusive evaluation option license, and
                                              addition to logistical and other resource                 The prospective exclusive evaluation                a subsequent exclusive
                                              factors to consider, a key element of site              option license territory may be                       commercialization license, may be
                                              selection is a successful compliance                    worldwide, and the field of use may be                granted unless the NIH receives written
                                              record with FDA or another Agency                       limited to:                                           evidence and argument that establishes
                                              with which we have a memorandum of                         1. Exclusive use of the Licensed Patent            that the grant of the license would not
                                              understanding. If a site visit involves a               Rights to develop a test kit approved by the          be consistent with the requirements of
                                              visit to a separate physical location of                FDA as a Class III medical device under the           35 U.S.C. 209 and 37 CFR part 404
                                              another firm under contract to the                      Premarket approval (PMA) process, such test           within fifteen (15) days from the date of
                                              applicant, the other firm also needs to                 kit to be distributed in commerce for the             this published notice.
                                              agree to participate in the program, as                 purpose of identifying subgroups of breast               Complete applications for a license in
                                              well as have a satisfactory compliance                  cancer, colorectal cancer, and non-small cell         the field of use filed in response to this
                                                                                                      lung cancer patients that may benefit from
                                              history.                                                                                                      notice will be treated as objections to
                                                                                                      treatment with a taxane therapy; and
                                              III. Requests for Participation                            2. Non-exclusive use of the Licensed Patent        the grant of the contemplated exclusive
                                                                                                      Rights to develop a test kit for which the FDA        evaluation option license. Comments
                                                 Identify requests for participation                  issues an order, in the form of a letter, which       and objections submitted to this notice
                                              with the docket number found in                         finds Licensee’s device to be substantially           will not be made available for public
                                              brackets in the heading of this                         equivalent to one or more similar legally             inspection and, to the extent permitted
                                              document. Received requests are                         marketed devices, and states that the                 by law, will not be released under the
                                              available for public examination in the                 Licensee’s device can be marketed in the U.S.         Freedom of Information Act, 5 U.S.C.
                                              Division of Dockets Management (see                     (i.e., 510(k) cleared), such test kit to be           552.
                                              ADDRESSES) between 9 a.m. and 4 p.m.,                   distributed in commerce for the purpose of
                                                                                                      identifying subgroups of breast cancer,                 Dated: February 9, 2015.
                                              Monday through Friday.
                                                                                                      colorectal cancer, and non-small cell lung            Richard U. Rodriguez,
                                                Dated: February 10, 2015.                             cancer patients that may benefit from                 Acting Director, Office of Technology
                                              Leslie Kux,                                             treatment with a taxane therapy.                      Transfer, National Institutes of Health.
                                              Associate Commissioner for Policy.                         Upon the expiration or termination of              [FR Doc. 2015–03088 Filed 2–13–15; 8:45 am]
                                              [FR Doc. 2015–03117 Filed 2–13–15; 8:45 am]             the exclusive evaluation option license,              BILLING CODE 4140–01–P
                                              BILLING CODE 4164–01–P                                  Taxor Diagnostics, LLC will have the
                                                                                                      exclusive right to execute an exclusive
                                                                                                      commercialization license which will                  DEPARTMENT OF HEALTH AND
                                              DEPARTMENT OF HEALTH AND                                supersede and replace the exclusive                   HUMAN SERVICES
                                              HUMAN SERVICES                                          evaluation option license with no
                                                                                                      greater field of use and territory than               National Institutes of Health
                                              National Institutes of Health                           granted in the exclusive evaluation
                                                                                                      option license.                                       National Institute of Environmental
                                              Prospective Grant of Exclusive                                                                                Health Sciences; Notice of Closed
                                              License: Start-up Evaluation License                    DATES: Only written comments or
                                                                                                                                                            Meeting
                                              for the Development of Theranostic                      applications for a license (or both)
                                              Kits for Taxane-based Chemotherapy                      which are received by the NIH Office of                 Pursuant to section 10(d) of the
                                                                                                      Technology Transfer on or before March                Federal Advisory Committee Act, as
                                              AGENCY:    National Institutes of Health,               4, 2015 will be considered.                           amended (5 U.S.C. App.), notice is
                                              HHS.                                                    ADDRESSES: Requests for copies of the                 hereby given of the following meeting.
                                              ACTION:   Notice.                                       patent application, inquiries, comments,                The meeting will be closed to the
                                              SUMMARY:    This is notice, in accordance               and other materials relating to the                   public in accordance with the
                                              with 35 U.S.C. 209 and 37 CFR part 404,                 contemplated exclusive evaluation                     provisions set forth in sections
                                              that the National Institutes of Health,                 option license should be directed to:                 552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
                                              Department of Health and Human                          Patrick McCue, Ph.D., Licensing and                   as amended. The grant applications and
                                              Services, is contemplating the grant to                 Patenting Manager, Office of                          the discussions could disclose
                                              Taxor Diagnostics, LLC of an exclusive                  Technology Transfer, National Institutes              confidential trade secrets or commercial
                                              evaluation option license to practice the               of Health, 6011 Executive Boulevard,                  property such as patentable material,
                                              inventions embodied in the following                    Suite 325, Rockville, MD 20852–3804;                  and personal information concerning
                                              US Patent, US Patent Application, and                   Telephone: (301) 435–5560; Facsimile:                 individuals associated with the grant
                                              International Patent Application (and all               (301) 402–0220; Email: mccuepat@                      applications, the disclosure of which
                                              foreign counterparts): US Patent No.                    mail.nih.gov.                                         would constitute a clearly unwarranted
                                              8,546,091, issued 01 October 2013,                      SUPPLEMENTARY INFORMATION:    The                     invasion of personal privacy.
                                              entitled, ‘‘Akt Phosphorylation at                      technology describes a method of                        Name of Committee: National Institute of
                                              SER473 as an Indicator for Taxane-                      identifying cancer patients that will                 Environmental Health Sciences Special
                                                                                                                                                            Emphasis Panel; Worker Health and Safety
tkelley on DSK3SPTVN1PROD with NOTICES




                                              based Chemotherapy’’ [HHS Ref. E–191–                   respond favorably to and benefit from
                                              2009/0–US–07]; US Patent Application                                                                          Training Review.
                                                                                                      treatment with taxane-based therapy
                                                                                                                                                              Date: March 9–10, 2015.
                                              serial no. 14/031,699, of the same name,                depending on the phosphorylation                        Time: 8:00 a.m. to 5:00 p.m.
                                              filed 19 September 2013 [HHS Ref. E–                    status of protein Akt-Serine 473 in                     Agenda: To review and evaluate grant
                                              191–2009/0–US–08]; and International                    patient’s tumor biopsy sample.                        applications.
                                              (PCT) Patent Application no. PCT/                          The prospective exclusive evaluation                 Place: Sheraton Chapel Hill Hotel, One
                                              US2010/035816, of the same name, filed                  license is being considered under the                 Europa Drive, Chapel Hill, NC 27517.



                                         VerDate Sep<11>2014   16:51 Feb 13, 2015   Jkt 235001   PO 00000   Frm 00046   Fmt 4703   Sfmt 4703   E:\FR\FM\17FEN1.SGM   17FEN1


                                                                          Federal Register / Vol. 80, No. 31 / Tuesday, February 17, 2015 / Notices                                                8331

                                                Contact Person: Sally Eckert-Tilotta, Ph.D.,            The meetings will be closed to the                    Date: March 20, 2015.
                                              Scientific Review Officer, National Institute           public in accordance with the                           Time: 11:00 a.m. to 3:00 p.m.
                                              of Environmental Health Sciences, Office of             provisions set forth in sections                        Agenda: To review and evaluate grant
                                              Program Operations, Scientific Review                                                                         applications.
                                                                                                      552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,              Place: National Cancer Institute Shady
                                              Branch, P.O. Box 12233, Research Triangle
                                              Park, NC 27709, (919) 541–1446, eckertt1@
                                                                                                      as amended. The grant and/or proposal                 Grove, 9609 Medical Center Drive, Room
                                              niehs.nih.gov.                                          applications and the discussions could                7W538, Rockville, MD 20850, (Telephone
                                              (Catalogue of Federal Domestic Assistance
                                                                                                      disclose confidential trade secrets or                Conference Call).
                                              Program Nos. 93.115, Biometry and Risk                  commercial property such as patentable                  Contact Person: Ivan Ding, M.D. Health
                                              Estimation—Health Risks from                            material, and personal information                    Scientist Administrator, Program & Review
                                              Environmental Exposures; 93.142, NIEHS                  concerning individuals associated with                Extramural Staff Training Branch, Division of
                                              Hazardous Waste Worker Health and Safety                the grant applications, the disclosure of             Extramural Activities, National Cancer
                                              Training; 93.143, NIEHS Superfund                                                                             Institute, 9609 Medical Center Drive, Room
                                                                                                      which would constitute a clearly
                                              Hazardous Substances—Basic Research and                                                                       7W534, Bethesda, MD 20892–9750, 240–276–
                                                                                                      unwarranted invasion of personal                      6444, dingi@mail.nih.gov.
                                              Education; 93.894, Resources and Manpower               privacy.
                                              Development in the Environmental Health                                                                         Name of Committee: National Cancer
                                              Sciences; 93.113, Biological Response to                  Name of Committee: National Cancer                  Institute Special Emphasis Panel; NCI Small
                                              Environmental Health Hazards; 93.114,                   Institute Special Emphasis Panel; R13                 Grants Program for Cancer Research.
                                              Applied Toxicological Research and Testing,             Conference Grant Review.                                Date: March 24–25, 2015.
                                              National Institutes of Health, HHS)                       Date: March 3, 2015.                                  Time: 8:00 a.m. to 5:00 p.m.
                                                                                                        Time: 1:00 p.m. to 5:00 p.m.                          Agenda: To review and evaluate grant
                                                Dated: February 10, 2015.                               Agenda: To review and evaluate contract             applications.
                                              Carolyn Baum,                                           proposals.                                              Place: Hyatt Regency Bethesda, One
                                              Program Analyst, Office of Federal Advisory               Place: National Cancer Institute Shady              Bethesda Metro Center, 7400 Wisconsin
                                              Committee Policy.                                       Grove, 9609 Medical Center Drive, Room                Avenue, Bethesda, MD 20814.
                                                                                                      7W556, Rockville, MD 20850, (Telephone                  Contact Person: Viatcheslav A.
                                              [FR Doc. 2015–03094 Filed 2–13–15; 8:45 am]
                                                                                                      Conference Call).                                     Soldatenkov, Ph.D., M.D., Scientific Review
                                              BILLING CODE 4140–01–P                                    Contact Person: Bratin K. Saha, Ph.D.,              Officer, Special Review Branch, Division of
                                                                                                      Scientific Review Officer, Program                    Extramural Activities, National Cancer
                                                                                                      Coordination and Referral Branch, Division            Institute, NIH, 9609 Medical Center Drive,
                                              DEPARTMENT OF HEALTH AND                                of Extramural Activities, National Cancer             Room 7W254, Bethesda, MD 20892–8329,
                                              HUMAN SERVICES                                          Institute, 9609 Medical Center Drive, Room            240–276–6378, soldatenkovv@mail.nih.gov.
                                                                                                      7W556, Rockville, MD 20850, 240–276–6411,
                                                                                                                                                              Name of Committee: National Cancer
                                              National Institutes of Health                           sahab@mail.nih.gov.
                                                                                                                                                            Institute Special Emphasis Panel; AIDs
                                                                                                        Name of Committee: National Cancer                  Malignancy Consortium (AMC).
                                              National Institute on Aging; Amended                    Institute Special Emphasis Panel; Core                  Date: March 26–27, 2015.
                                              Notice of Meeting                                       Infrastructure & Methodological Research for            Time: 6:30 p.m. to 4:00 p.m.
                                                                                                      Cancer Epidemiology Cohorts (U01).                      Agenda: To review and evaluate grant
                                                Notice is hereby given of a change in                   Date: March 12, 2015.                               applications.
                                              the meeting of the National Institute on                  Time: 10:00 a.m. to 6:00 p.m.                         Place: Bethesda North Marriott Hotel &
                                                                                                        Agenda: To review and evaluate grant                Conference Center 5701 Marinelli Road,
                                              Aging Special Emphasis Panel, April 06,
                                                                                                      applications.                                         Bethesda, MD 20852.
                                              2015, 11:00 a.m. to April 06, 2015, 1:00                  Place: National Cancer Institute Shady
                                              p.m., National Institute on Aging,                                                                              Contact Person: Bratin K. Saha, Ph.D.,
                                                                                                      Grove, 9609 Medical Center Drive, Room                Scientific Review Officer, Program
                                              Gateway Building, 7201 Wisconsin                        6W032, Rockville, MD 20850, (Telephone                Coordination and Referral Branch, Division
                                              Avenue, Suite 2C212, Bethesda, MD                       Conference Call).                                     of Extramural Activities, National Cancer
                                              20892 which was published in the                          Contact Person: Viatcheslav A.                      Institute, NIH, 9609 Medical Center Drive,
                                              Federal Register on February 9, 2015,                   Soldatenkov, Ph.D., M.D., Scientific Review           Room 7W556, Rockville, MD 20850, 240–
                                              80 FR 7003.                                             Officer, Special Review Branch, Division of
                                                                                                                                                            276–6411, sahab@mail.nih.gov.
                                                                                                      Extramural Activities, National Cancer
                                                The meeting notice is amended to                      Institute, 9609 Medical Center Drive, Room              Name of Committee: National Cancer
                                              change the date of the meeting from                     7W254, Bethesda, MD 20892–8329, 240–276–              Institute Special Emphasis Panel; Cancer
                                              April 6, 2015 to March 30, 2015. The                    6378, soldatenkovv@mail.nih.gov.                      Intervention and Surveillance Modeling.
                                              meeting is closed to the public.                                                                                Date: April 1–2, 2015.
                                                                                                        Name of Committee: National Cancer
                                                                                                                                                              Time: 12:00 p.m. to 4:00 p.m.
                                                Dated: February 10, 2015.                             Institute Special Emphasis Panel; Vacutubes
                                                                                                                                                              Agenda: To review and evaluate grant
                                                                                                      to Preserve the Viability of Circulating Tumor
                                              Melanie J. Gray,                                                                                              applications.
                                                                                                      Cells.
                                              Program Analyst, Office of Federal Advisory               Date: March 19, 2015.                                 Place: National Cancer Institute Shady
                                              Committee Policy.                                         Time: 10:30 a.m. to 2:30 p.m.                       Grove, 9609 Medical Center Drive, Room
                                                                                                        Agenda: To review and evaluate grant                7W554, Rockville, MD 20850, (Telephone
                                              [FR Doc. 2015–03091 Filed 2–13–15; 8:45 am]
                                                                                                      applications.                                         Conference Call).
                                              BILLING CODE 4140–01–P                                                                                          Contact Person: Christopher L. Hatch,
                                                                                                        Place: National Cancer Institute Shady
                                                                                                      Grove, 9609 Medical Center Drive, Room                Ph.D., Chief, Health Scientific Administrator,
                                                                                                      7W538, Rockville, MD 20850, (Telephone                Program Coordination and Referral Branch,
                                              DEPARTMENT OF HEALTH AND                                Conference Call).                                     Division of Extramural Activities, National
                                              HUMAN SERVICES                                            Contact Person: Ivan Ding, M.D., Health             Cancer Institute, NIH, 9609 Medical Center
                                                                                                      Scientist Administrator, Program & Review             Drive, Room 7W554, Rockville, MD 20850,
                                              National Institutes of Health                           Extramural Staff Training Branch, Division of         240–276–6454, ch29v@nih.gov.
                                                                                                      Extramural Activities, National Cancer                  Information is also available on the
tkelley on DSK3SPTVN1PROD with NOTICES




                                              National Cancer Institute; Notice of                    Institute, 9609 Medical Center Drive, Room            Institute’s/Center’s home page: http://
                                              Closed Meetings                                         7W534, Bethesda, MD 20892–9750, 240–276–              deainfo.nci.nih.gov/advisory/sep/sep.htm,
                                                                                                      6444, dingi@mail.nih.gov.                             where an agenda and any additional
                                                Pursuant to section 10(d) of the                        Name of Committee: National Cancer                  information for the meeting will be posted
                                              Federal Advisory Committee Act, as                      Institute Special Emphasis Panel; Predictive          when available.
                                              amended (5 U.S.C. App.), notice is                      Biomarkers of Adverse Reactions to                    (Catalogue of Federal Domestic Assistance
                                              hereby given of the following meetings.                 Radiation Treatment.                                  Program Nos. 93.392, Cancer Construction;



                                         VerDate Sep<11>2014   16:51 Feb 13, 2015   Jkt 235001   PO 00000   Frm 00047   Fmt 4703   Sfmt 4703   E:\FR\FM\17FEN1.SGM   17FEN1



Document Created: 2015-12-18 13:19:55
Document Modified: 2015-12-18 13:19:55
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesMarch 9-10, 2015.
FR Citation80 FR 8330 

2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR